The Latin America, Middle East and Africa Cluster Headache Market would witness market growth of 7.8% CAGR during the forecast period (2022-2028).
The cycle of a headache might be shortened by using prescription drugs. These may lessen the intensity of the headaches. Verapamil, lithium carbonate, divalproex sodium, calcium channel blockers, melatonin, and topiramate are possible treatments. In addition, a new preventative treatment is a monoclonal antibody against the calcitonin gene-related peptide (CGRP). If necessary, cluster headaches have been treated surgically in the past. The use of gentle electrical stimulation on the neck is one approach. Another inserts a medical device through the top gums to produce electrical stimulation.
A rise in the introduction of different monoclonal antibodies for cluster headaches and an increase in the number of novel medications being tested in clinical trials by significant firms are expected to benefit the market's expansion. Also, it is projected that an increase in the number of cluster headache drugs in development would fuel market growth.
Saudi Arabia Pharmaceuticals’ mission is to accelerate the development of the region's manufacturing cluster and transition to more complex goods with an emphasis on those crucial for national security. With the total net worth of $120 billion and an excellent export prospect, the Saudi pharmaceutical industry is one of the fastest-growing in the world today. The Saudi pharmaceutical sector grew by over 5% CAGR in 2018 to reach 8.2 billion dollars in sales. Up to 2025, the industry is anticipated to expand at a 5% annual pace to reach $10 Bn. The substantial investment and the growing number of initiatives by the government to develop the pharmaceutical sector will provide innovative and enhanced treatment options for the cluster headache, which will propel the market growth in the LAMEA.
The Brazil market dominated the LAMEA Cluster Headache Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $8.6 Million by 2028. The Argentina market is experiencing a CAGR of 8.3% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 7.5% during (2022 - 2028).
Based on Distribution channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Type, the market is segmented Episodic, and Chronic. Based on Drug Class, the market is segmented into Triptans, Calcium Channel Blockers, Ergot Derivatives, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Cluster Headache Market is Predict to reach $437.5 Million by 2028, at a CAGR of 4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
By Distribution channel
By Type
By Drug Class
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 